JUN 22, 2021 7:49 AM PDT

Evaluating adverse effects of induction therapy for neuroblastoma

A study published in the Journal of Clinical Oncology reports an evaluation of the chemotherapy treatment given to children with neuroblastomas.The study evaluated the two treatments used by the European Neuroblastoma Study Group and the US equivalent, finding that while both are effective, the European regimen is better tolerated by young patients. 

Treatment for high-risk neuroblastomas involves several combination chemotherapies that aim to shrink the tumor before surgery (known as induction therapy). "With the European rCOJEC regimen, high-grade vomiting, nausea, diarrhea, infections and stomatitis were significantly lower than in the US reference group. We will therefore implement it as a standard of care for high-risk neuroblastoma," says senior study author Professor Ruth Ladenstein, MD, MBA, cPM, who heads up the Studies & Statistics for Integrated Research and Projects (S2IRP) group at St. Anna Children's Cancer Research Institute where the study was conducted. 

The study was coordinated by The European Neuroblastoma Study Group of the International Society of Pediatric Oncology (SIOPEN) and included data from 630 patients with a median age of 3.2 years. The patients were randomly assigned to one of the two regimens: the MSKCC-N5 regimen from Memorial Sloan Kettering Cancer Center or the rCOJEC regimen, which is the standard SIOPEN treatment in Europe.

They found that while the efficacy of the two treatments did not significantly differ, the rate of high-grade (grade 3-4), acute adverse events was significantly higher with the MSKCC-N5 regimen.

Although this study focused on quality of life, the researchers point to the need to develop improved efficacy in treatments, given that only about 60 and 65 percent of children receiving the rCOJEC and -MSKCC-N5 regimens, respectively, are still alive after three years. 

"We urgently need to further improve the survival outcome. For example, the combination of chemotherapy with anti-GD2 antibodies is very promising - a combination that will be tested in randomized trials by SIOPEN and others," concludes Professor Ladenstein.

Sources: Journal of Clinical Oncology, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
SEP 06, 2021
Cancer
A New Biomarker to Personalize Breast Cancer Therapy
SEP 06, 2021
A New Biomarker to Personalize Breast Cancer Therapy
The American Cancer Society estimates that over 280,000 women in the United States will be diagnosed with breast cancer ...
OCT 07, 2021
Cancer
Dual Threat: CAR T Cells Modified to Target Two Neuroblastoma Antigens
OCT 07, 2021
Dual Threat: CAR T Cells Modified to Target Two Neuroblastoma Antigens
Neuroblastoma is a cancer of immature nerve cells found in various areas, including the adrenal glands, neck, chest ...
OCT 12, 2021
Immunology
Cancer Drug Helps Alzheimer's Mice Remember
OCT 12, 2021
Cancer Drug Helps Alzheimer's Mice Remember
What if a drug—specifically developed to treat one disease—had the potential to address other non-related co ...
OCT 26, 2021
Immunology
Two Different Arms, Twice the Cancer-Killing Potential?
OCT 26, 2021
Two Different Arms, Twice the Cancer-Killing Potential?
Our immune system has developed an arsenal of sophisticated molecular weapons to defend us against the continuous barrag ...
DEC 19, 2021
Cancer
An Antibody to Clear the Way for Drug Delivery to Tumors
DEC 19, 2021
An Antibody to Clear the Way for Drug Delivery to Tumors
Tumors require blood vessels to obtain nutrients and growth factors needed for their expansion.  Many tumors effici ...
JAN 06, 2022
Cancer
Breakthrough COVID Cases Cause Concern for Cancer Patients
JAN 06, 2022
Breakthrough COVID Cases Cause Concern for Cancer Patients
As we enter the third year of the COVID-19 pandemic, we continue to learn more about the respiratory virus leading to a ...
Loading Comments...